Key takeaways
- IPAY 2027 Ibrance (palbociclib) Medicare-negotiated price effective date, second negotiation cycle
- IPAY 2028 Kisqali (ribociclib) and Verzenio (abemaciclib) Medicare-negotiated price effective date, third negotiation cycle, one year later
- 3 of 3 approved CDK4/6 inhibitors now inside the Medicare Drug Price Negotiation Program, the entire class
- 0.95–0.98 adjusted hazard ratios across the class in the 2025 Flatiron equivalence study, no clinical differentiation to defend a higher negotiated price
All three CDK4/6 inhibitors are under Medicare price negotiation, staggered a year apart: Ibrance's negotiated price takes effect January 2027, Kisqali's and Verzenio's not until January 2028.
Every approved CDK4/6 inhibitor for HR+/HER2- metastatic breast cancer is now inside the IRA's Medicare Drug Price Negotiation Program, an unusual situation: a full drug class negotiated simultaneously, not just one competitor. Ibrance (palbociclib) was selected in the program's second cycle, with its negotiated price effective 1 January 2027. Kisqali (ribociclib) and Verzenio (abemaciclib) were selected a cycle later, in the third round, with negotiations running through 2026 and prices effective 1 January 2028. That one-year stagger is not a technicality. Ibrance's negotiated price becomes public first, and CMS's own negotiation history from earlier cycles becomes a reference point the agency can use when it sits down with Novartis and Lilly a year later.
The staggered timeline collides directly with the class's own clinical profile. A 2025 real-world study of 9,146 US patients found no significant overall-survival difference between the three drugs, meaning none of the three manufacturers can lean on superior clinical data to defend a higher negotiated price once CMS has Ibrance's number in hand. Our price ladder models what CMS is likely to extract from Kisqali and Verzenio given the Ibrance precedent, the GTN erosion each manufacturer already absorbs through commercial rebates, and the launch-sequencing question of whether Part D formulary placement shifts once negotiated prices take effect a year apart rather than together.
The CDK4/6 inhibitor class under Medicare price negotiation — staggered a year apart
| Agent | Manufacturer | IRA Negotiation Cycle | Negotiated Price Effective |
|---|---|---|---|
| Ibrance (palbociclib) | Pfizer | Second cycle | 1 January 2027 |
| Kisqali (ribociclib) | Novartis | Third cycle | 1 January 2028 |
| Verzenio (abemaciclib) | Lilly | Third cycle | 1 January 2028 |
Sources: CMS Medicare Drug Price Negotiation Program fact sheets (IPAY 2027, IPAY 2028); Rugo HS et al., Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2- metastatic breast cancer in the US real-world setting, ESMO Open 2025.
What this model answers
Every section answers a named commercial question your team is asking, scoped to your asset.
- Why does Ibrance's Medicare-negotiated price become public a full year before Kisqali's and Verzenio's, and what does that precedent do to the later negotiation? • IPAY 2027 vs IPAY 2028 negotiation cycle mechanics • how CMS uses prior-cycle outcomes as reference points • the sequencing risk for Novartis and Lilly
- With no survival difference across the class, what argument does a manufacturer actually have left in an IRA negotiation? • The Flatiron equivalence finding applied to negotiation leverage • non-clinical differentiators (formulation, dosing, tolerability) as the remaining negotiation levers • GTN erosion modelling
- How should Part D formulary placement and rebate strategy change once negotiated prices take effect a year apart rather than simultaneously? • Part D formulary-tier modelling across the staggered effective dates • rebate and GTN waterfall scenarios • launch-sequencing recommendation for the class
What's inside
-
1 · The Binding Constraint 2 pp
- Why the one-year negotiation stagger, not the drugs' own economics, sets the pricing problem
- Pressure-tested against the class-wide equivalence finding before the rest of the model is built out
-
2 · Price Ladder — IRA Negotiation Cycles 3 pp
- IPAY 2027 versus IPAY 2028 negotiation mechanics
- Where each manufacturer's WAC and GTN position sits ahead of negotiation
-
3 · Precedent Risk — Ibrance as the Reference Point 3 pp
- How CMS uses a prior cycle's negotiated price as a benchmark for the next
- What Novartis and Lilly can and cannot argue against that precedent
-
4 · Analogue Benchmarks — CDK4/6 Class Economics 3 pp
- Class-wide WAC, GTN, and rebate positioning
- What the equivalence finding means for defensible pricing
-
5 · Value-Based Argument Without Clinical Differentiation 3 pp
- What remains to argue when survival outcomes don't differ
- Formulation, dosing, and tolerability as the residual negotiation levers
-
6 · GTN Waterfall & Part D Rebate Scenarios 3 pp
- Statutory, negotiated, and commercial-rebate components decomposed line by line
- How the waterfall shifts once negotiated prices land a year apart
-
7 · Launch Sequencing & Revenue Scenarios 4 pp
- Formulary-tier and revenue implications of the staggered effective dates
- Conservative, base, and aggressive revenue scenarios through 2028
-
8 · Client Alignment Questions 2 pp
- The open pricing questions your team must close before the 2026 negotiation round
- Structured for an internal pricing committee session
Appendix and source ledger included · 45-minute analyst readout included with delivery
Custom model delivered in 72 hours.
Assess this reportIncluded with every brief
Get Started
Commission this model
AXLRx delivers oncology pricing strategy models built for market access and pricing teams navigating IRA negotiation cycles and staggered precedent risk. Custom model in 72 hours.
- 1. Submit your requestSpecify your indication, market basket, and comparator scope.
- 2. Scoping callAXLRx analyst confirms pricing mechanism assumptions and WTP threshold before building.
- 3. DeliveryResearch-verified pricing model in 72 hours with optional analyst readout.
How AXLRx builds this model
Prepared by MoatRx analysts on the AXLRx commercial consulting engine.
Every AXLRx pricing model is built from primary regulatory sources (CMS, FDA) and live negotiation-tracking documentation, not secondary summaries. Findings are independently verified before inclusion.
US HR+/HER2- mBC pricing sources: CMS Medicare Drug Price Negotiation Program fact sheets for IPAY 2027 and IPAY 2028, and Rugo HS et al., ESMO Open 2025, for the class-wide clinical equivalence finding.
- Ibrance's IPAY 2027 selection and negotiated-price effective date verified against CMS Medicare Drug Price Negotiation Program fact sheets
- Kisqali and Verzenio's IPAY 2028 (third cycle) selection verified against the same CMS documentation
- Class-wide overall-survival equivalence verified against Rugo HS et al., ESMO Open 2025
Frequently asked questions
Deliverables What formats are included with every model?
Every commissioned Pricing Strategy Model includes an editable 12-sheet Excel model (Price Ladder, ERP Basket, Analogue Benchmarks, Value-Based ICER, GTN Waterfall, Launch Sequencing, Revenue Scenarios, Sensitivity, HTA Landscape, QC, Sources) and a PDF methodology brief — no PowerPoint deck, since a pricing model is built to be worked in directly, not presented from. An optional 45-minute analyst readout call is included.
Sources How is the pricing evidence verified?
AXLRx builds from primary sources only — regulatory databases (CMS, FDA), HTA body publications, and live negotiation-tracking documentation. No secondary summaries or market research reports. Every reference price, cycle date, and clinical input is independently verified before inclusion.
Customisation Can I model a specific market basket or comparator set?
Yes. The intake form captures your indication, target market basket, comparator class, and WTP threshold. A scoping call confirms scope before research starts. Commission via the intake form to start.